ANTI-DIABETIC therapy Jardiance has now also been approved by the TGA for prescription to reduce the risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease.
Jardiance (empagliflozin) marketed in Australia by Boehringer Ingelheim and Lilly has been given the new indication following the findings of the landmark EMPA-REG OUTCOME study published in the New England Journal of Medicine.
The research found the addition of empagliflozin to the current standard of care, for patients with type 2 diabetes and established cardiovascular disease, resulted in a 38% reduction in the risk of cardiovascular death.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Jan 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Jan 17
